The results are also consistent with previous findings on [18F] DPA‐714 TSPO‐PET, a marker of microglia activation, in patients with prodromal AD and AD dementia, where higher levels of baseline microglia PET showed protective effects on the clinical progression (Hamelin et al, 2016, 2018). The gene discussed is TSPO; the disease is Alzheimer disease.